FAS

FAS Full Name

Fas cell surface death receptor

FAS Introduction

FAS (Fas cell surface death receptor), also known as CD95 or APO-1, is a transmembrane receptor that belongs to the tumor necrosis factor receptor (TNFR) superfamily and serves as one of the most important regulators of programmed cell death. The receptor is encoded by the FAS gene and is broadly expressed on the surface of many cell types, particularly activated lymphocytes, epithelial cells, and immune-related tissues. In normal physiology, controlled elimination of damaged, infected, or unnecessary cells is essential for maintaining tissue homeostasis and immune balance. The FAS signaling pathway provides a direct molecular mechanism to trigger apoptosis when cells become harmful or dysfunctional. Because abnormal cell survival is a major driver of cancer and chronic inflammatory diseases, researchers increasingly focus on the FAS receptor as a key molecular checkpoint that determines whether cells survive or undergo programmed death.

At the functional level, FAS acts as a death receptor that becomes activated when it binds to its ligand, Fas ligand (FASL). This interaction induces receptor trimerization and the recruitment of adaptor proteins such as FADD, leading to the formation of the death-inducing signaling complex (DISC). DISC assembly activates initiator caspases, especially caspase-8, which then triggers the downstream caspase cascade responsible for apoptosis. Recent mechanistic studies have revealed that the regulation of FAS signaling is more complex than previously thought. After activation, the receptor can undergo endocytosis and enter intracellular trafficking pathways where its signaling intensity and duration are tightly controlled. Proteins involved in endosomal recycling, including Rab11 and ENTR1-dependent pathways, influence whether FAS receptors are recycled back to the cell surface or targeted for degradation. This intracellular sorting process directly affects the strength and persistence of apoptotic signaling, highlighting a spatial regulatory mechanism that may provide new opportunities for therapeutic intervention in diseases where apoptosis is dysregulated.

Abnormalities in the FAS/FASL signaling system are strongly associated with multiple human diseases, particularly cancers, immune disorders, and virus-associated malignancies. Genetic studies have demonstrated that certain single-nucleotide polymorphisms in the FAS gene are significantly associated with altered susceptibility to cancers such as gastric cancer, suggesting that inherited differences in apoptosis regulation may influence individual cancer risk. In the tumor microenvironment, the FAS/FASL axis can also contribute to immune evasion. For example, elevated expression of FASL in virus-associated tumors such as cervical cancer may promote apoptosis of tumor-infiltrating T lymphocytes, allowing malignant cells to escape immune surveillance. In addition, transcriptomic and bioinformatic analyses have identified FAS as a key component of gene signatures related to programmed cell death and tumor prognosis. Altered FAS expression levels have been linked to clinical outcomes in several cancers, where higher expression may correlate with improved immune response and better prognosis in certain tumor types. These findings highlight the dual role of FAS as both a regulator of apoptosis and a clinically relevant biomarker, making it an increasingly important target for cancer biology, immunology research, and therapeutic development.

Alternate Names for FAS

FAS; Fas cell surface death receptor; APT1; CD95; FAS1; APO-1; FASTM; ALPS1A; TNFRSF6; tumor necrosis factor receptor superfamily member 6

• 1.Asgari R, et al.; Fas cell surface death receptor/Fas ligand genetic variants in gastric cancer patients: A case-control study. Indian J Med Res. 2022 Jul;156(1):77-82.
  2.Wang Z, et al.; A novel necroptosis-related gene signature associated with immune landscape for predicting the prognosis of papillary thyroid cancer. Front Genet. 2022, 13:947216.